TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19969409

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (E2V) and dienogest (DNG) administered over 20 cycles with a specific dosing schedule: E2V 3 mg on days 1 and 2, E2V 2 mg/DNG 2 mg on days 3-7, E2V 2 mg/DNG 3 mg on days 8-24, E2V 1 mg on days 25 and 26, and placebo on days 27 and 28.
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (E2V) and dienogest (DNG) in subgroup of women aged 18-35 years (998 participants).
Number of subjects: 1377
Study: 17414737

Group type: EXPERIMENTAL
Intervention: Lithium levels preceding reappearance of manic or mixed symptomatology
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lithium levels preceding reappearance of depressive symptoms
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Logistic regression analyses
Number of subjects: 86
Study: 15457373

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alpha-blockers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Choline (substituting extracellular sodium)
Number of subjects: 20
Study: 11145109

Group type: EXPERIMENTAL
Intervention: High-fat (40% of daily energy), high-monounsaturated-fat diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fat (30% of daily energy) diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study: 9352757

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Optimal intermittent positive pressure ventilation (IPPV)
Number of subjects: 10
Study: 7654577

Group type: EXPERIMENTAL
Intervention: AC/DC iontophoresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional DC method
Number of subjects: 0

Group type: COMPARATOR
Intervention: AC without DC-offset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC with DC-offset
Number of subjects: 0
Study: 3741729

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3596872

Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl)-rutosides (HR) 3 g/day for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31912929

Group type: EXPERIMENTAL
Intervention: EQUIA Forte
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theracal LC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other materials
Number of subjects: 0
Study: 31087442

Group type: EXPERIMENTAL
Intervention: 22-NAP (22:00 to 00:00)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 00-NAP (00:00 to 02:00)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 02-NAP (02:00 to 04:00)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (not explicitly defined)
Number of subjects: 14
Study: 29871226

Group type: EXPERIMENTAL
Intervention: Smart-phone application
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional oral health education (Control)
Number of subjects: 65
Study: 26039521

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg) + Ezetimibe (10 mg)
Number of subjects: 18144

Group type: COMPARATOR
Intervention: Simvastatin (40 mg) + Placebo
Number of subjects: 18144
Study: 23222038

Group type: EXPERIMENTAL
Intervention: Cognitive analytic therapy (CAT) - 24 sessions over 10 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 78
Study: 21983067

Group type: COMPARATOR
Intervention: Probiotic intervention (Lactobacillus rhamnosus + Bifidobacterium longum and Lactobacillus paracasei + Bifidobacterium longum) given to mothers 2 months prior to and 2 months after delivery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Probiotic intervention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Maternal colonization by B. bifidum
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Maternal probiotic treatment
Number of subjects: 80
Study: 19064829

Group type: EXPERIMENTAL
Intervention: MedDiet + VOO
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 1224
Study: 16773068

Group type: EXPERIMENTAL
Intervention: HPV testing in primary cervical screening
Number of subjects: 24510
Study: 15317834

Group type: EXPERIMENTAL
Intervention: Amiodarone + ximelagatran
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ximelagatran + amiodarone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ximelagatran
Number of subjects: 26
Study: 11020001

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alpha-2b and ribavirin for 24 weeks
Number of subjects: 428

Group type: COMPARATOR
Intervention: Interferon alpha-2b monotherapy for 48 weeks
Number of subjects: 428
Study: 9279534

Group type: EXPERIMENTAL
Intervention: L-arginine (0.52 mg kg‐1 min‐1)
Number of subjects: 25
Study: 8334811

Group type: EXPERIMENTAL
Intervention: Clenbuterol treatment for 4 weeks postoperatively
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks postoperatively
Number of subjects: 20
Study: 3595666

Group type: EXPERIMENTAL
Intervention: High dose metoclopramide
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone added to metoclopramide
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study: 30066815

Group type: EXPERIMENTAL
Intervention: MARA group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MARA+SMS group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MARA group vs MARA+SMS group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adiposity measures
Number of subjects: 120
Study: 27543277

Group type: EXPERIMENTAL
Intervention: Pakistani almonds (10 g/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: American almonds (10 g/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No-intervention (NI)
Number of subjects: 150
Study: 26685032

Group type: EXPERIMENTAL
Intervention: Impulsivity-focused group intervention (8 weekly sessions)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no group intervention)
Number of subjects: 78
Study: 23414589

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with three cycles of TPF followed by concurrent chemoradiotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone with two cycles of bolus cisplatin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 145
Study: 20958842

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18227667

Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pulse oximetry and respiratory-rate assessment
Number of subjects: 54
Study: 16750345

Group type: EXPERIMENTAL
Intervention: 100 mg of DHA daily for 14 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: 100 mg of olive oil as placebo daily for 14 days
Number of subjects: 27
Study: 14659345

Group type: EXPERIMENTAL
Intervention: ROLL intervention using 2 megabecquerels of (99m)Tc-MAA injected directly into the lesion under image guidance.
Number of subjects: 63
Study: 10871462

Group type: EXPERIMENTAL
Intervention: Urine cultures
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Blood cultures
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy changes
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 391
Study: 8924099

Group type: EXPERIMENTAL
Intervention: Whirlpool baths (tub group)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 785
Study: 1396626

Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 0
Study: 3885921

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 6 L/min via nonrebreathing face masks for 15 minutes or less
Number of subjects: 19

Group type: COMPARATOR
Intervention: Air inhalation at 6 L/min via nonrebreathing face masks for 15 minutes or less
Number of subjects: 19
Study: 30863472

Group type: EXPERIMENTAL
Intervention: Transcutaneous Pulsed Radiofrequency (TPRF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 50
Study: 30118351

Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: No periodontal therapy (control)
Number of subjects: 100
Study: 26313017

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gelatin Sponge
Number of subjects: 40
Study: 23276715

Group type: EXPERIMENTAL
Intervention: 80 kV
Number of subjects: 60
Study: 22388884

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg daily
Number of subjects: 366

Group type: COMPARATOR
Intervention: Gefarnate 50 mg twice daily
Number of subjects: 366
Study: 19908928

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam
Number of subjects: 0
Study: 17786079

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15177521

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazepril HCl combination therapy (5/20 mg/d titrated to 10/20 mg/d)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazepril HCl combination therapy
Number of subjects: 364

Group type: COMPARATOR
Intervention: Amlodipine besylate monotherapy (5 mg/d titrated to 10 mg/d)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Amlodipine besylate monotherapy
Number of subjects: 364
Study: 11156753

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9498468

Group type: EXPERIMENTAL
Intervention: ETEC/rCTB vaccine (E003)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 8002507

Group type: EXPERIMENTAL
Intervention: Strength training program (16 weeks)
Number of subjects: 22
Study: 3264141

Group type: COMPARATOR
Intervention: Cardioplegic solution without allopurinol (Group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cardioplegic solution with 100 mg allopurinol (Group 2)
Number of subjects: 14
Study: 30789807

Group type: EXPERIMENTAL
Intervention: 1000 mg of calcium and 800 IU vitamin D supplementation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo group with neither calcium nor vitamin D supplementation
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Bat haplotype
Number of subjects: 151
Study: 31124942

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL) first group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Video Laryngoscopy (VL) first group
Number of subjects: 20
Study: 29018027

Group type: EXPERIMENTAL
Intervention: RDN plus SSAHT
Number of subjects: 106

Group type: COMPARATOR
Intervention: SSAHT alone
Number of subjects: 106
Study: 26691637

Group type: EXPERIMENTAL
Intervention: Baseline HRV
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Change in HRV
Number of subjects: 282
Study: 24518763

Group type: EXPERIMENTAL
Intervention: Ultrasound guided transversus abdominis plane block
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surgeon administered regional field infiltration with bupivacaine
Number of subjects: 32
Study: 22338626

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (200 g/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional yogurt (200 g/day)
Number of subjects: 70
Study: 19416560

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural minimal contact bibliotherapy, delivered via the book 'Doctor, I Hope it's Nothing Serious?', containing cognitive behavioural theory and exercises.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list condition (control group)
Number of subjects: 0
Study: 17627016

Group type: EXPERIMENTAL
Intervention: High tertile of total serum IgE
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Middle tertile of total serum IgE
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Specific IgE to common aeroallergens (defined as >or=0.35 kU/L)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Total serum IgE levels before treatment
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Mean levels of all immunoglobulins (IgA, IgM, IgG)
Number of subjects: 467
Study: 15899724

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: glimepiride 2 mg/day
Number of subjects: 95
Study: 12032397

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9650373

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (0.5 mg administered intracervically)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Dilapan S rods (four hygroscopic rods applied intracervically)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Estradiol gel (150 mg administered intravaginally)
Number of subjects: 247
Study: 9506204

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1850128

Group type: EXPERIMENTAL
Intervention: High fat-low fiber diet (96 g fat/day, 6 g fiber/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low fat-high fiber diet (33 g fat/day, 41 g fiber/day)
Number of subjects: 43
Study: 7039667

Group type: EXPERIMENTAL
Intervention: Adrenaline 1% combined with guanethidine 1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adrenaline 1%
Number of subjects: 20
Study: 30903306

Group type: EXPERIMENTAL
Intervention: iGEL
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Air‐Q intubating laryngeal airway
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Ambu AuraGain disposable laryngeal mask
Number of subjects: 116
Study: 27370941

Group type: EXPERIMENTAL
Intervention: Paracetamol 1g IV
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ketorolac 30mg IV
Number of subjects: 100
Study: 25342708

Group type: EXPERIMENTAL
Intervention: AG2 (bed rest and six periods of 5 min AG daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: AG1 (bed rest and 30 min of AG daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (bed rest without countermeasures)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: AG1 and AG2
Number of subjects: 11
Study: 25524951

Group type: EXPERIMENTAL
Intervention: Blood 25-hydroxyvitamin D concentration <50 nmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood 25-hydroxyvitamin D concentration
Number of subjects: 0
Study: 23474735

Group type: EXPERIMENTAL
Intervention: Interactive virtual telerehabilitation system
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional out-patient physical therapy
Number of subjects: 142
Study: 21741446

Group type: EXPERIMENTAL
Intervention: Fuzhisan (FZS, 10mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19028407

Group type: EXPERIMENTAL
Intervention: Alefacept plus MTX
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 160
Study: 16779510

Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cryosurgery and Conventional stripping
Number of subjects: 40
Study: 14757693

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Beating heart surgery
Number of subjects: 300
Study: 11783697

Group type: EXPERIMENTAL
Intervention: ceftazidime 2 g t.i.d. (n=12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: imipenem/cilastatin 1 g t.i.d. (n=15)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both ceftazidime and imipenem
Number of subjects: 27
Study: 10102907

Group type: EXPERIMENTAL
Intervention: Near-patient CRP test using NycoCard(R) CRP
Number of subjects: 1853

Group type: COMPARATOR
Intervention: Control group (mailing blood samples for CRP measurements)
Number of subjects: 1853
Study: 7521815

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 2527732

Group type: EXPERIMENTAL
Intervention: Procaterol 100 micrograms
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 594790

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES, 5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus DES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orchiectomy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31238372

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 27804203

Group type: EXPERIMENTAL
Intervention: Wake therapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Light therapy (30 min daily for 9 weeks)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ongoing psychoeducation regarding good sleep hygiene
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall treatment experience
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 13
Study: 26011718

Group type: EXPERIMENTAL
Intervention: Mental skills training
Number of subjects: 2432

Group type: COMPARATOR
Intervention: Military history (control)
Number of subjects: 2432
Study: 22527135

Group type: EXPERIMENTAL
Intervention: Supervised exercise combined with TENS for the first 3 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Supervised exercise without TENS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (Supervised exercise with and without TENS)
Number of subjects: 66
Study: 21359522

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg) plus rebamipide (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rabeprazole (20 mg)
Number of subjects: 0
Study: 19843657

Group type: EXPERIMENTAL
Intervention: Lu 35‐138 (I(Kr)‐blocking antipsychotic compound)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lu 35‐138
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: MCS as a covariate
Number of subjects: 79
Study: 16389665

Group type: EXPERIMENTAL
Intervention: Isometric exercise (5 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Body scanning (control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sitting passively (control)
Number of subjects: 60
Study: 15214594

Group type: EXPERIMENTAL
Intervention: FOLFOX regimen (oxaliplatin, infusional 5-FU, leucovorin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative 5-FU-based chemotherapy combined with irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative combined-modality therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral capecitabine (Xeloda) as a radiation enhancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFOX and FOLFIRI regimens
Number of subjects: 0
Study: 11426361

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gelatin
Number of subjects: 42
Study: 9105077

Group type: EXPERIMENTAL
Intervention: Inspiratory elastic load of 18 cm H2O/L
Number of subjects: 11
Study: 10451950

Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ceftizoxime
Number of subjects: 107
Study: 2630295

Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (3 mg) in decaffeinated coffee
Number of subjects: 40
Study: 235013

Group type: EXPERIMENTAL
Intervention: Pimozide (mean 18.8 mg/day for 6 weeks)
Number of subjects: 18
Study: 31167457

Group type: EXPERIMENTAL
Intervention: Game Over Intervention (GOI)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control condition (effective learning program)
Number of subjects: 362
Study: 28950297

Group type: EXPERIMENTAL
Intervention: CRLX101 + bevacizumab
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 111
Study: 25228137

Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream (IVM 1%) once daily
Number of subjects: 962

Group type: COMPARATOR
Intervention: Metronidazole 0.75% cream (MTZ 0.75%) twice daily
Number of subjects: 962
Study: 23319069

Group type: EXPERIMENTAL
Intervention: Printed decision support intervention
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Computer-assisted decision support intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 33
Study: 21531671

Group type: EXPERIMENTAL
Intervention: Actual Reiki therapy
Number of subjects: 189

Group type: COMPARATOR
Intervention: Sham Reiki placebo
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 189
Study: 19750999

Group type: EXPERIMENTAL
Intervention: Prophylactic radiation therapy (700 cGy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no radiation therapy)
Number of subjects: 0
Study: 16984677

Group type: EXPERIMENTAL
Intervention: Preventive intervention (counseling and support for mother-infant relationship)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Routine primary care (control)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Preventive intervention
Number of subjects: 151